AURA1 Inhibitors

Chemical inhibitors of AURA1 include a range of compounds that target the kinase activity essential for its function in cell cycle regulation. Alisertib, for instance, binds to the ATP-binding pocket of AURA1, preventing the binding and utilization of ATP which is critical for AURA1's kinase activity. This interruption of ATP binding directly inhibits the phosphorylation capability of AURA1, a crucial step in its functional cycle. Similarly, MLN8054 and MLN8237 are selective inhibitors that also engage with the ATP-binding site of AURA1. By occupying this site, they block the access of ATP, thus inhibiting the kinase activity of AURA1 and its subsequent phosphorylation of substrates. VX-680, or MK-0457, extends this inhibitory effect across AURA1, AURA1B, and AURA1C isoforms, ensuring a broad inhibition of AURA1's associated activities. Danusertib and AT9283 also exploit the ATP-binding site of AURA1 to inhibit its function. By preventing ATP from activating the enzyme, these compounds directly reduce the phosphorylating action of AURA1.

Barasertib and Hesperadin serve as examples of inhibitors that, while not solely specific to AURA1, affect its function due to their action on closely related kinases within the cell division cycle. Barasertib's inhibition of Aurora kinase B indirectly affects AURA1's role, given the collaborative function of these kinases during mitosis. Hesperadin, in inhibiting Aurora kinases, disrupts AURA1 activity by competitive binding to the active site, a strategy that impedes the kinase's normal operation. CCT137690 and SNS-314 target the ATP-binding pocket, which further emphasizes the vulnerability of AURA1's ATP-binding domain to chemical inhibition. This specific targeting ensures a direct suppression of AURA1's kinase activity. PHA-739358, as a pan-Aurora kinase inhibitor, binds within the same ATP pocket, leading to a comprehensive inhibition of AURA1 and its related kinases, thus impeding the phosphorylation cascade necessary for cell cycle progression. These inhibitors collectively demonstrate a focused approach to repressing the catalytic action of AURA1 and highlight the ATP-binding site as a critical area for functional disruption.